Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET
Uppsala, Sweden – October 22, 2021 – As previously communicated Orexo will announce the Q3 2021 Interim Report, on November 3 at 8 am CET. The same day at 1 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Dennis Urbaniak, EVP Digital Therapeutics and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to firstname.lastname@example.org, no later than 11 am CET.
Please view the instructions below on how to participate.
To dial in:
SE +46 8 505 583 56
UK +44 333 300 92 70
US +1 646 722 49 56
Prior to the event the presentation material will be available on Orexo´s website under Investors/Reports, Presentations and Audiocasts.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine/naloxone products, where Orexo commercializes its lead product, ZUBSOLV®, for treatment of opioid use disorder. Total net sales for Orexo in 2020 amounted to SEK 664 million and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.